PepGen (NASDAQ:PEPG) Earns “Buy” Rating from HC Wainwright

PepGen (NASDAQ:PEPG)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports.

Several other research firms have also recently issued reports on PEPG. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Sunday, June 7th. Craig Hallum started coverage on PepGen in a research report on Tuesday, June 16th. They set a “buy” rating and a $11.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of PepGen in a report on Friday, August 28th. Finally, Wedbush decreased their target price on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

PepGen Price Performance

NASDAQ:PEPG opened at $3.21 on Wednesday. The firm has a market capitalization of $222.32 million, a price-to-earnings ratio of -2.45 and a beta of 1.97. The company’s 50-day moving average is $2.52 and its two-hundred day moving average is $2.73. PepGen has a 1-year low of $1.31 and a 1-year high of $7.80.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. As a group, equities analysts anticipate that PepGen will post -1.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PepGen

Several institutional investors have recently bought and sold shares of PEPG. RA Capital Management L.P. increased its stake in PepGen by 87.7% during the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock worth $92,698,000 after purchasing an additional 9,375,000 shares during the period. Commodore Capital LP increased its stake in PepGen by 31.6% during the 1st quarter. Commodore Capital LP now owns 4,475,000 shares of the company’s stock worth $7,921,000 after buying an additional 1,075,000 shares during the period. Viking Global Investors LP boosted its position in PepGen by 134.9% in the 3rd quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after buying an additional 2,000,000 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of PepGen in the second quarter worth $4,664,000. Finally, Vivo Capital LLC purchased a new stake in shares of PepGen during the third quarter worth $10,742,000. 58.01% of the stock is owned by institutional investors and hedge funds.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).